Bazedoxifene: A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis

Abstract

Spanish

French

Objective:

To review clinical studies and other available literature regarding the development, pharmacology, toxicology, pharmacokinetics/pharmacodynamics, adverse effects, and place in therapy of bazedoxifene, a selective estrogen receptor modulator (SERM), currently in Phase III clinical trials for the treatment and prevention of postmenopausal osteoporosis.

Data Sources:

A literature search was performed of PubMed (1966–February 2007). International Pharmaceutical Abstracts (1970–February 2007), Web of Science (1975–February 2007), Biological Abstracts (1926–2007), and Google Scholar (2001–February 2007) databases, using the search terms bazedoxifene, TSE-424, Indole-33, WAY-140424, selective estrogen receptor modulator, and SERM. In addition, product information was requested from the manufacturer, and www.clinicaltrials.gov was searched for unpublished Phase III clinical trials in progress.

Study Selection and Data Extraction:

Articles on Phase I and II trials were selected for review, as well as articles discussing preclinical development of bazedoxifene. At the time of writing, no articles on Phase III trials were available for review. Abstracts of unpublished data were reviewed, as was information provided by the manufacturer.

Data Synthesis:

Bazedoxifene is a third-generation SERM currently in Phase III clinical trials. It has been found to act as an agonist on skeletal tissue, with bone turnover reduced by 20–25% with doses of 20 or 40 mg daily. In addition, bazedoxifene has been found to be an antagonist on breast tissue and uterine tissue, demonstrating inhibition of breast tissue proliferation and decreased endometrial stimulation as the dose is increased.

Conclusions:

Current literature suggests that bazedoxifene will likely be safe and effective when used in the treatment of postmenopausal osteoporosis. Completion of Phase III clinical trials will more fully elucidate the safety and efficacy profile of bazedoxifene, as well as more clearly define its place in therapy.

Keywords

bazedoxifene osteoporosis selective estrogen receptor modulator women's health

Get full access to this article

View all access options for this article.

References

International Osteoporosis Foundation. Osteoporosis and you. www.osteofound.org/publications/pdf/osteoporosis_and_you.pdf (accessed 2006 Jun 26).

National Osteoporosis Foundation. Fast facts. www.nof.org/osteoporosis/diseasefacts.htm (accessed 2006 Jun 26).

American Association of Clinical Endocrinologists' medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition with selected updates for 2003. Endocr Pract 2003; 9: 545–64.

Morello

Wurz

DeGregorio

. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361–72.

Tamoxifen. Klasco

, ed. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, expires 2007 Dec 31 (accessed 2007 Jan 11).

Package insert. Evista (raloxifene hydrochloride). Indianapolis, IN: Eli Lilly and Company, July 2003.

Gruber

. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004;5:1086–93.

Komm

Kharode

Bodine

Harris

Miller

Lyttle

. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999–4008.

Ronkin

Northington

Baracat

. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397–404.

10.

Miller

Harris

Komm

. Bazedoxifene acetate: selective estrogen receptor modulator treatment and prevention of osteoporosis. Drugs Fut 2002;27:117–21.

11.

Komm

Lyttle

. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317–26.

12.

Patat

McKeand

Baird-Bellaire

Ermer

LeCoz

. Absolute/relative bioavailability of bazedoxifene acetate in healthy postmenopausal women (abstract). Clin Pharmacol Ther 2003;73: P43.

13.

Chandrasekaran

Ermer

McKeand

. Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women (abstract). Clin Pharmacol Ther 2003;73: P47.

14.

Ermer

McKeand

Sullivan

Parker

Orczyk

. Bazedoxifene acetate dose proportionality in healthy, postmenopausal women (abstract). Clin Pharmacol Ther 2003;73: P46.

15.

Ronkin

Clarke

Boudes

Constantine

. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion (abstract). J Bone Miner Res 2001;16: S413.

16.

Boudes

Ronkin

Korner

Baracat

Constantine

. Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain (abstract). Osteoporos Int 2003;14: S14.

17.

Fracture incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoporotic postmenopausal women. (Identifier: NCT00205777). www.clinicaltrials.gov. Search term “bazedoxifene” (accessed 2006 Jun 16).

18.

Bone mineral density increase and safety of TSE-424 compared to placebo in osteoporotic postmenopausal women. (Identifier: NCT00238745). www.clinicaltrials.gov. Search term “bazedoxifene” (accessed 2006 Jun 16).

19.

A double-blind, randomized, placebo-controlled, efficacy and safety study of bazedoxifene/conjugated estrogen combinations for treatment of vasomotor symptoms associated with menopause. (Identifier: NCT00234819). www.clinicaltrials.gov. Search term “bazedoxifene” (accessed 2006 Jun 16).

20.

A double-blind, randomized, placebo- and active-controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for prevention of endometrial hyperplasia and prevention of osteoporosis in postmenopausal women. (Identifier: NCT00242710). www.clinicaltrials. gov. Search term “bazedoxifene” (accessed 2006 Jun 16).

21.

A double-blind, randomized, placebo- and active-controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. (Identifier: NCT00238732). www.clinicaltrials.gov. Search term “bazedoxifene” (accessed 2006 Jun 16).

22.

Baird

McKeand

Ermer

Patat

Garcia-Queglas

. Lack of clinically relevant pharmacokinetic interaction between bazedoxifene and ibuprofen (abstract). Clin Pharmacol Ther 2002;71: P94.

23.

Benhamou

. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007;74:39–47. Epub 28 Nov 2006. DOI 10.1016/j.jbspin.2006.06.004